financial guidance
The drugmaker is hyping its recent acquisition announcement against an overall 29 percent revenue decline and 4 percent oncology sales dip during Q1 2023.
Quest Adds to Cancer Portfolio With $450M Buy of Haystack Oncology; Q1 Revenues Down 11 Percent
Premium
The firm said the acquisition let it move into the "fast growing" MRD space and round out its offerings in cancer screening, pathology, and sequencing.
The Swiss firm reported solid sales growth across its oncology portfolio during the first quarter of 2023 as overall sales increased 3 percent.
The drugmaker is expecting Trodelvy sales to increase even more this year if the FDA approves a broader breast cancer indication later this month.
Merck's Keytruda Sales Increase 19 Percent in Q4; Lynparza Reaches Blockbuster Status in 2022
Premium
During an earnings call, the company's executives detailed strategies for replacing revenue from its bestselling drug Keytruda, slated to lose market exclusivity in coming years.